会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • 3-아릴-5-알킬-1,2,4-옥사다이아졸 유도체, 그 제조방법 및이를 포함하는 비만 예방 또는 치료용 조성물
    • 3-芳基-5-烷基-1,2,4-氧杂噻唑衍生物及其制备方法,以及用于预防或治疗含有其的成分的组合物
    • KR100847448B1
    • 2008-07-21
    • KR1020070028181
    • 2007-03-22
    • 한국화학연구원
    • 안미자정명희조남옥이병호
    • C07D271/06C07D413/06A61K31/535A61P3/04
    • 3-Aryl-5-alkyl-1,2,4-oxadiazole derivatives are provided to reduce eating by competing with MCH R1(melanin-concentrating hormone receptor subtype-1) associated with obesity, so that the compounds are useful for preventing or treating obesity. The 3-aryl-5-alkyl-1,2,4-oxadiazole derivatives represented by the formula(1) are useful as antagonist of MCH R1, wherein R1 is (C3-C5) branched alkyl, (C1-C3)dialkylamino(C1-C3)alkyl or (C1-C3) linear alkyl which is optionally substituted by pyridine, piperidine or (C5-C7) cycloalkyl; R2 is halogen-substituted phenyl, CF3-substituted phenyl, phenyl substituted by phenoxy which is optionally substituted by halogen or (benzo[1,3]dioxol-5-yl)phenyl; and X is -NHCO or -NHCONH-. A method for preparing the 3-aryl-5-alkyl-1,2,4-oxadiazole derivatives represented by the formula(1a) comprises the steps of: (1) reacting 4-aminobenzonitrile represented by the formula(2) with organic acid(R2COOH) in the presence of solvent and binding reagent to prepare amide compounds represented by the formula(3); (2) reacting the amide compounds represented by the formula(3) with hydroxylamine hydrochloride in the presence of solvent to prepare amidoxime represented by the formula(4); and (3) reacting the amidoxime represented by the formula(4) with another organic acid(R1COOH) in the presence of solvent and binding reagent to prepare 1,2,4-oxadiazole ring.
    • 提供3-芳基-5-烷基-1,2,4-恶二唑衍生物以通过与与肥胖相关的MCH R1(黑色素浓缩激素受体亚型-1)竞争来减少进食,使得该化合物可用于预防或治疗 肥胖。 由式(1)表示的3-芳基-5-烷基-1,2,4-恶二唑衍生物可用作MCH R 1的拮抗剂,其中R 1是(C 3 -C 5)支链烷基,(C 1 -C 3)二烷基氨基( C1-C3)烷基或任选被吡啶,哌啶或(C5-C7)环烷基取代的(C1-C3)直链烷基; R 2是卤素取代的苯基,CF 3取代的苯基,被苯氧基取代的苯基,其被卤素或(苯并[1,3]二氧杂环戊烯-5-基)苯基任选取代; X是-NHCO或-NHCONH-。 制备由式(1a)表示的3-芳基-5-烷基-1,2,4-恶二唑衍生物的方法包括以下步骤:(1)使由式(2)表示的4-氨基苄腈与有机酸 (R2COOH)在溶剂和结合试剂存在下反应制备式(3)表示的酰胺化合物。 (2)在溶剂存在下使式(3)表示的酰胺化合物与羟胺盐酸盐反应,制备由式(4)表示的偕胺肟; 和(3)在溶剂和结合试剂的存在下使由式(4)表示的偕胺肟与另一种有机酸(R1COOH)反应以制备1,2,4-恶二唑环。
    • 6. 发明公开
    • 5-(4-치환된-[1,2,5]티아디아졸-3-일)-3-메틸-1,2,3,4-테트라하이드로피리미딘 유도체와 이의 제조방법
    • 5-(4-取代 - (1,2,5)哒嗪-3-基)-3-甲基-1,2,3,4-四氢嘧啶衍生物及其制备方法
    • KR1020020017137A
    • 2002-03-07
    • KR1020000050262
    • 2000-08-29
    • 한국화학연구원
    • 정명희이미정공재양
    • C07D417/14
    • PURPOSE: Provided are 5-(4-Substituted-(1,2,5)thiadiazole-3-yl)-3-methyl-1,2,3,4-tetrahydropyrimidine derivatives which are a muscarinic receptor agonists and used as therapeutic agents in Alzheimer's disease. Also, provided are their pharmaceutically acceptable salt, their preparation process and their use. CONSTITUTION: 5-(4-Substituted-(1,2,5)thiadiazole-3-yl)-3-methyl-1,2,3,4-tetrahydropyrimidine derivatives are represented by the formula(1), wherein X represents dialkylamine group, piperidinyl group, morpholinyl group or N-methylpiperazinyl group. They are as follows: 3-dimethyl-(4-(3-methyl-1,2,3,4-tetrahydropyrimidine-5-yl)-(1,2,5)thiadiazole-3-yl)amine; 3-methyl-5-(4-pyrrolidine-1-yl-(1,2,5)thiadiazole-3-yl)-1,2,3,4-tetrahydropyrimidine; 3-methyl-5-(4-piperidine-1-yl-(1,2,5)thiazol-3-yl)-1,2,3,4-tetrahydropyrimidine; 4-(4-(3-methyl-1,2,3,4-tetrahydropyrimidine-5-yl)-(1,2,5)thiadiazole-3-yl)morpholine or 3-methyl-5-(4-(4-methylpiperazin-1-yl)-(1,2,5)thiadiazole-3-yl)-1,2,3,4-tetrahydropyrimidine. The therapeutic agent in Alzheimer's disease contains 5-(4-Substituted-(1,2,5)thiadiazole-3-yl)-3-methyl-1,2,3,4-tetrahydropyrimidine derivative or its pharmaceutically acceptable salt.
    • 目的:提供作为毒蕈碱受体激动剂并用作治疗剂的5-(4-取代 - (1,2,5)噻二唑-3-基)-3-甲基-1,2,3,4-四氢嘧啶衍生物 在阿尔茨海默病。 此外,还提供其药学上可接受的盐,其制备方法及其用途。 构成:5-(4-取代的 - (1,2,5)噻二唑-3-基)-3-甲基-1,2,3,4-四氢嘧啶衍生物由式(1)表示,其中X表示二烷基胺 哌啶基,吗啉基或N-甲基哌嗪基。 它们如下:3-二甲基 - (4-(3-甲基-1,2,3,4-四氢嘧啶-5-基) - (1,2,5)噻二唑-3-基)胺; 3-甲基-5-(4-吡咯烷-1-基 - (1,2,5-)噻二唑-3-基)-1,2,3,4-四氢嘧啶; 3-甲基-5-(4-哌啶-1-基 - (1,2,5)噻唑-3-基)-1,2,3,4-四氢嘧啶; 4-(4-(3-甲基-1,2,3,4-四氢嘧啶-5-基) - (1,2,5)噻二唑-3-基)吗啉或3-甲基-5-(4-( 4-甲基哌嗪-1-基) - (1,2,5-)噻二唑-3-基)-1,2,3,4-四氢嘧啶。 阿尔茨海默病中的治疗剂含有5-(4-取代 - (1,2,5)噻二唑-3-基)-3-甲基-1,2,3,4-四氢嘧啶衍生物或其药学上可接受的盐。
    • 9. 发明授权
    • 세펨 유도체의 제조방법
    • 制备CEPHEM衍生物的方法
    • KR1019930007811B1
    • 1993-08-20
    • KR1019900016941
    • 1990-10-23
    • 한국화학연구원
    • 김완주정명희하재두
    • C07D501/24
    • 3-Vinylcephem derivatives of formula (I) which are useful as an oral antibiotics and it's intermediates were prepd. from 7- aminocephalosporin. In (I), R1=H or aralkanoyl as (A) or oxyimino substd. aralkanoyl or hetero aralkanoyl as (B), R2=Cl, Br, R3= phenyl or mono substd. phenyl or cyclohexadienyl, R4= 2- aminothiazolyl, R5= methylacetic acid or dimethylacetic acid. Cpd. (I) have better absorption and antibacterial activity against Gram negative bacteria for oral use than existing oral cephems.
    • 可用作口服抗生素的式(I)的3-乙烯基头孢烯衍生物及其中间体是制备的。 来自7-氨基头孢菌素。 在(I)中,R 1 = H或芳烷酰基(A)或氧亚氨基。 芳烷酰基或杂芳烷酰基作为(B),R 2 = Cl,Br,R 3 =苯基或单子取代。 苯基或环己二烯基,R 4 = 2-氨基噻唑基,R 5 =甲基乙酸或二甲基乙酸。 CPD。 (I)对口腔使用革兰氏阴性细菌的吸收和抗菌活性比现有的口腔流行病好。